Pharmaceuticals, Biotechnology and Life Sciences
Novartis has ended third quarter 2019 with reported net income of $2.0 billion, which as an 8% increase, driven by higher operating income and higher income from associated companies, saying in the press release Tuesday that its EPS was USD 0.90 (+11%, +14% cc), growing faster than net income driven by lower weighted average number of shares outstanding.
AstraZeneca on Monday said that that the US Food and Drug Administration (FDA) has approved Farxiga (dapagliflozin) to reduce the risk of hospitalisation for heart failure (hHF) in adults with type-2 diabetes (T2D) and established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors.
Amgen and UCB said Friday that Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has re-examined and recommended Marketing Authorization for Evenity (romosozumab) for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture and with no history of myocardial infarction or stroke.
Verona Pharma has randomized the last patient in its Phase 2b dose-ranging study evaluating the effect of nebulized ensifentrine as an add-on to treatment with a long acting bronchodilator in patients with moderate-to-severe chronic obstructive pulmonary disease (“COPD”).
Cytel Inc., the leading global provider of innovative analytical software and consulting services to the life sciences industry, has announced its Complex Innovative Trial Design Symposium and East Training event, which will bring together industry-leading experts to discuss innovative solutions to pressing challenges including rare disease clinical trials, and will also offer delegates an in-depth East software training session.
The FDA has accepted for review Foamix’s New Drug Application (NDA) for FMX103 (minocycline topical foam 1.5%) topical foam, for the treatment of moderate-to-severe papulopustular rosacea in adults.
The UN Political Declaration has for a goal to treat 40 million people for TB disease in the 5-year period 2018-22, and 7 million have already been treated in 2018.
Roche on Wednesday reported 10% raise in sales in the third yearly quarter of 2019, backed by new products, while its Pharmaceuticals Division sales went up 12%, driven by high demand for recently launched medicines, mainly Ocrevus, Hemlibra, Tecentriq and Perjeta.
Gilead Sciences has appointed Andrew Dickinson, who currently serves as the company’s Executive Vice President, Corporate Development and Strategy, as Chief Financial Officer (CFO), effective November 1, while remaining a member of the senior leadership team, reporting to Daniel O’Day, Chairman and Chief Executive Officer.
Allergan’s shareholders have voted to approve to be bought by AbbVie Inc for approximately $63 billion, as more than 99 percent of the votes cast were in favor of the transaction, representing about 69% of the shares outstanding and eligible to be voted at each of the Allergan shareholder meetings held on October 14, 2019 in Dublin, Ireland.